Beam Therapeutics annual ebitda
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics EBITDA Growth & History (BEAM)
Beam Therapeutics's calculated EBITDA was −$361.4M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$361.4M | $32.2M | — |
| 2024 | 2024-12-31 | −$393.6M | −$237.2M | — |
| 2023 | 2023-12-31 | −$156.5M | $167.9M | — |
| 2022 | 2022-12-31 | −$324.3M | $60.7M | — |
| 2021 | 2021-12-31 | −$385.0M | −$257.0M | — |
| 2020 | 2020-12-31 | −$128.0M | −$56.4M | — |
| 2019 | 2019-12-31 | −$71.7M | — | — |
Beam Therapeutics quarterly ebitda
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$121.1M | −$6.5M | — |
| Q1 2026 | 2026-03-31 | −$101.6M | $12.1M | — |
| Q4 2025 | 2025-12-31 | −$11.8M | $82.8M | — |
| Q3 2025 | 2025-09-30 | −$121.3M | −$20.2M | — |
| Q2 2025 | 2025-06-30 | −$114.6M | −$15.3M | — |
| Q1 2025 | 2025-03-31 | −$113.8M | −$15.1M | — |
| Q4 2024 | 2024-12-31 | −$94.6M | −$232.8M | — |
| Q3 2024 | 2024-09-30 | −$101.0M | $2.1M | — |
| Q2 2024 | 2024-06-30 | −$99.3M | −$2.0M | — |
| Q1 2024 | 2024-03-31 | −$98.7M | −$4.4M | — |
| Q4 2023 | 2023-12-31 | $138.2M | $223.3M | — |
| Q3 2023 | 2023-09-30 | −$103.1M | −$15.3M | — |
| Q2 2023 | 2023-06-30 | −$97.3M | −$18.8M | — |
| Q1 2023 | 2023-03-31 | −$94.3M | −$21.4M | — |
| Q4 2022 | 2022-12-31 | −$85.0M | −$24.2M | — |
| Q3 2022 | 2022-09-30 | −$87.8M | −$19.9M | — |
| Q2 2022 | 2022-06-30 | −$78.5M | −$21.2M | — |
| Q1 2022 | 2022-03-31 | −$72.9M | $126.1M | — |
| Q4 2021 | 2021-12-31 | −$60.9M | −$21.3M | — |
| Q3 2021 | 2021-09-30 | −$67.9M | −$31.8M | — |
| Q2 2021 | 2021-06-30 | −$57.3M | −$32.2M | — |
| Q1 2021 | 2021-03-31 | −$199.0M | −$171.7M | — |
| Q4 2020 | 2020-12-31 | −$39.5M | −$14.2M | — |
| Q3 2020 | 2020-09-30 | −$36.1M | −$19.0M | — |
| Q2 2020 | 2020-06-30 | −$25.1M | −$8.3M | — |
| Q1 2020 | 2020-03-31 | −$27.3M | −$14.9M | — |
| Q4 2019 | 2019-12-31 | −$25.4M | — | — |
| Q3 2019 | 2019-09-30 | −$17.1M | — | — |
| Q2 2019 | 2019-06-30 | −$16.8M | — | — |
| Q1 2019 | 2019-03-31 | −$12.4M | — | — |
Beam Therapeutics ebitda trends
Over the last five fiscal years, Beam Therapeutics's ebitda decreased from −$128.0M to −$361.4M, a change of −$233.4M. The latest reported quarter, Q2 2026, shows −$121.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...
